Company profile for Eleva

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Eleva Biologics is a clinical-stage biopharmaceutical company pioneering the development of biologics using a proprietary moss-based expression platform. Our innovative pipeline includes therapies for unmet medical needs, such as Factor H for C3 Glomerulopathy (C3G) and a novel treatment for Fabry disease, currently in Phase 1/2 trials. By leveraging our advanced manufacturing technology, we aim to produce complex biologics ef...
Eleva Biologics is a clinical-stage biopharmaceutical company pioneering the development of biologics using a proprietary moss-based expression platform. Our innovative pipeline includes therapies for unmet medical needs, such as Factor H for C3 Glomerulopathy (C3G) and a novel treatment for Fabry disease, currently in Phase 1/2 trials. By leveraging our advanced manufacturing technology, we aim to produce complex biologics efficiently, delivering transformative therapies to improve patient outcomes worldwide.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Hans-Bunte-Str. 19 79108 Freiburg
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/21/3169943/0/en/Eleva-advances-CPV-104-into-Phase-1b-clinical-testing-in-patients-with-C3G-following-the-successful-completion-of-single-ascending-dose-evaluation-in-healthy-volunteers.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/07/07/3110749/0/en/Eleva-administers-first-dose-of-its-Factor-H-biological-treatment-in-C3-Glomerulopathy-to-healthy-volunteers.html

GLOBENEWSWIRE
07 Jul 2025

https://www.globenewswire.com/news-release/2025/05/13/3079775/0/en/Eleva-Appoints-Donato-Spota-as-Chief-Financial-Officer.html

GLOBENEWSWIRE
13 May 2025

https://www.pharmiweb.com/press-release/2025-02-04/eleva-and-3pbiovian-sign-strategic-gmp-manufacturing-and-technology-alliance-to-boost-capacity-for-eleva-s-platform-and-pipeline

PHARMAWEB
04 Feb 2025

https://www.biospace.com/article/releases/eleva-enters-clinical-development-of-difficult-to-express-high-potential-proteins/?s=71

BIOSPACE
12 Oct 2021

https://www.biospace.com/article/releases/eleva-reaches-industrial-production-scale-and-prepares-for-clinical-development-of-factor-h/?s=71

BIOSPACE
14 Sep 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty